Yahoo Web Search

  1. Ad
    related to ELI LILLY AND COMPANY
  1. Calculating The Fair Value Of Eli Lilly and Company (NYSE:LLY)

    Simply Wall St. via Yahoo FinanceSep 05 11:54 AM

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Eli Lilly and Company (NYSE:LLY) as an investment opportunity by ...

  2. Stocks recently featured in the blog include: J&J JNJ, Eli Lilly LLY, Bristol-Myers BMY, Roche RHHBY and AbbVie ABBV. This week, J&J received an unfavorable ruling in the ...

  3. Eli Lilly and Company LLY announced that the FDA has approved its psoriasis drug Taltz (ixekizumab) for a new indication. Taltz injection (80 mg/mL) is now approved ...

  4. Developed by Eli Lilly and Co's Loxo Oncology and marketed by German drugmaker Bayer, it fights a rare genetic mutation that appears in less than 1% of solid tumors ...

  5. It has been about a month since the last earnings report for Eli Lilly (LLY). Will the recent positive trend continue leading up to its next earnings release, or is Lilly due for a pullback?

  6. Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert

    Zacks via Yahoo FinanceSep 16 12:33 PM

    The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.

  7. 4 Biotech Stocks With Big Catalysts in September

    Motley Fool via Yahoo FinanceSep 06 1:16 AM

    Investors cheered for Amgen's KRAS inhibitor, tentatively named AMG 510, when the company told us that five out of the first 10 evaluable patients with non-small cell lung cancer (NSCLC ...

  8. Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly ...

  9. Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

    Zacks via Yahoo FinanceSep 09 20:39 PM

    Eli Lilly and Company's LLY oral RET inhibitor selpercatinib (LOXO-292) demonstrated a 68% objective response rate (ORR) or shrinkage in tumor size in heavily pretreated ...

  10. In the study, treatment with Tagrisso showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS), increasing the time patients lived without ...

  1. Ads
    related to ELI LILLY AND COMPANY